Round table thematic science talks and discussions, set 1
Table 1: Aggression in children: unravelling gene-environment interplay to inform treatment and intervention
Location: Room 1
Leaders: Eero Vuoksimaa (FIMM), Alyce Whipp (FIMM), Miina Ollikainen (FIMM), Tellervo Korhonen (FIMM)
Aggression and its resulting consequences inflict a huge personal and financial burden on affected individuals and society. ACTION (Aggression in Children: Unravelling gene-environment interplay to inform treatment and intervention) is an EU-FP7-funded consortium, where the Kaprio and Ollikainen Groups are partners using FinnTwin 12 (Finnish twins born in 1983-87) data to investigate associations of aggression during childhood and adolescence with several outcomes later in life. Introduction to aggression including genetics as well as preliminary results regarding aggressive behavior and metabolites, and DNA methylation will be presented.
Table 2: A community-based effort to curate and standardize drug-target interaction data
Location: Room 2
Leaders: Jing Tang (FIMM), Zia Ur Rehman (FIMM)
Drug Target Commons (DTC) is a crowd-sourcing platform aimed to improve the consensus and use of drug-target interactions. Users can search, view, curate and download bioactivity data using various compound, target and publications identifiers. To facilitate the exchange of assay information, we adapted a specific bioassay ontology that standardizes the description of drug-target interaction assays. DTC not only contains wild type targets but also have data on disease-related mutated targets, which can have applications in drug repurposing. Further, the database features with a wiki function that enables an investigator not only to upload new data from their own experiments or literature survey, but also to participate in the workflow of annotation, integration and quality control together with the committed domain experts. Such an open environment ensures that most research discoveries are manually curated and cross-checked before being deposited in the DTC platform.
Table 3: Invertebrate model organisms in translational and basic research
Location: Room 3
Leaders: Anne von Philipsborn (DANDRITE), Duda Kvitsiani (DANDRITE), Sophie Seidenbecher (DANDRITE), Sadegh Navabi (DANDRITE)
Invertebrate model organisms have many advantages in translational and basic research. The speakers will focus on Drosophila and discuss how we can use this model organism to address fundamental questions in neuroscience. Non neuroscientists interested in using Drosophila in their own research are also very welcome to join the table and hear about general aspects of fly genetics and possibilities to study e.g. human disease in the fly.
Table 4: Pinpointing novel molecular disease mechanisms - targeting high-impact alleles
Location: Room 4
Leaders: Tiinamaija Tuomi (FIMM), Mervi Kinnunen (FIMM)
The identification and characterization of rare high-impact genomic variants may provide novel insights into disease pathogenesis. We will present preliminary results from academic and pharma-collaboration projects identifying low-frequency mutations of clinical significance. Examples of disease-causing mutations and protective variants will be presented.
Table 5: Interplay between proteins and lipid membranes in human disease
Location: Room 6
Leaders: Richard Lundmark (MIMS), Anna Överby (MIMS), Poul Nissen (DANDRITE)
Alterations in lipid composition and membrane tension are believed to influence structural rearrangements in proteins and the architecture of protein complexes and thereby protein function. How do proteins and lipids cooperate to maintain membrane function, and what goes wrong in disease? Can we find new ways to resolve lipid dynamics?
Table 6: RNA-mediated regulation in living cells
Location: Room 10
Leaders: Jörgen Johansson (MIMS), Vasili Haryuk (MIMS), Sun Nyunt Wai (MIMS)
During the last decade, RNA has been shown to control a multitude of regulatory events in living organisms. We will discuss different aspects of RNA regulation in both pro-and eukaryotes.
Table 7: Individualized systems medicine in solid tumors
Location: Room 11
Leaders: Astrid Murumägi (FIMM), Vilja Pietiäinen (FIMM)
We will discuss recent advances in precision medicine and its translation towards the clinic. Specifically, we will focus on the challenges in establishing patient-derived cell models from solid tumors, how to maintain their representativity and how they can be used in high throughput drug functional testing. We will highlight examples from our own experience from urological tumors and ovarian cancer.
Table 8: Genomes empowering predictive medicine
Location: Banquet Hall Side
Leaders: Hannele Laivuori (FIMM), Elisabeth Widén (FIMM), Riitta Sallinen (FIMM)
The advances in genomic sciences have paved the way to translate genome data into clinical practice, but new tools and procedures are needed to fully harness this opportunity. We will present three projects, the SiSU-database, the KardioKompassi application, and the Digital Health Revolution project, designed to enhance the use of genome information for early detection and targeted prevention.
Table 9: Functional genomics screens and analyzing big data
Leaders: Yevhen Akimov (FIMM), Alok Jaiswal (FIMM), Ashwini Kumar (FIMM)
High-throughput molecular profiling methods are frequently used to obtain a genome-scale portrait of genomic and transcriptomic landscape of tumors or cancer cell models. Similarly, genome-wide loss-of-function screens, based on RNAi or CRISPR, allow the interrogation of the functional landscape of cancer cells complementing the exploration of therapeutic landscape based on drug sensitivity screens. We will discuss these methods, the characteristics of the data produced and how to analyse them.
Table 10: Genetic, epigenetic, and molecular mechanisms of diabetes and obesity
Leaders: Anders Nykjær (DANDRITE), Sailalitha Bollepalli (FIMM), Leif Groop (FIMM)
Obesity and associated diabetes are becoming epidemic health problems in the Western world. Although unhealthy lifestyle is considered critical, an important role of heritability in their etiology is recognized, too. We will discuss recent genetic and epigenetic progress and the insight it has provided for understanding fundamental processes in metabolic control.
Table 11: Attacking our systemic flaws: scientist evaluation in career advancement
Leaders: Emmy Verschuren (FIMM), Ian Mills (NCMM)
How can we strengthen career prospects while maintaining the best science and most fair evaluation procedures?